A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
In June 2020, I was seeing consults in the damp, windowless basement of a community hospital in North Carolina.
